Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation.

Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation.

The androgen receptor (AR) is the principal therapeutic target in prostate cancer. For the past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus. However, some patients do not benefit, and those tumors that do initially respond to ADT eventually progress. One recentl...

Full description

Bibliographic Details
Main Authors: Lina Gao, Jacob Schwartzman, Angela Gibbs, Robert Lisac, Richard Kleinschmidt, Beth Wilmot, Daniel Bottomly, Ilsa Coleman, Peter Nelson, Shannon McWeeney, Joshi Alumkal
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3660401?pdf=render

Similar Items

Similar Items